Regen BioPharma, Inc.
RGBPP
Other OTC0.00
USD
+0.00
- -
Regen BioPharma, Inc.
RGBPP
(Other OTC)
Recent
price
0.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Regen BioPharma, Inc. (OTC: RGBPP) is a publicly traded biotechnology company focused on developing innovative regenerative medical applications, including autologous cell therapies, RNA- and DNA-based immunotherapies, and small molecules targeting immune-oncology and autoimmune disorders. The company advances novel technologies through pre-clinical and Phase I/II clinical trials, with a primary emphasis on modulating the immune checkpoint NR2F6 to treat cancer and autoimmune diseases; its pipeline features HemaXellerate, a stem cell-derived therapy for repairing damaged bone marrow in aplastic anemia and chemotherapy/radiation-treated patients; dCellVax and tCellVax, dendritic cell-based immunotherapies using gene silencing to stimulate immune responses; Dura-CAR, CAR-T cells enhanced with shRNA to inhibit NR2F6 for durable effectiveness; KimerApt, a platform of dual-function aptamers that bind and inhibit receptors like antibodies; DiffronC, small molecules and gene silencing for blood disorders; and BORIS, patented approaches modulating cancer stem cell processes. Founded in 2012 and headquartered in La Mesa, California, Regen BioPharma operates primarily in the United States, targeting niche markets such as rare hematological disorders and oncology with protected intellectual property encompassing 11 issued patents and 17 pending. Recent developments include FDA clearance for a Phase 1 trial of HemaXellerate, announced in 2024, with partnerships established with a leading clinical research organization for trial execution expected within 12-14 months; an ongoing Orphan Drug Designation application for HemaXellerate to secure regulatory benefits like tax credits and market exclusivity; and presentations at the Emerging Growth Conference highlighting expansion into chemotherapy-induced bone marrow suppression markets valued over $1 billion.